Following U.S. FDA Approval, Glenmark Plans Multi-Geography Launches For Crofelemer
This article was originally published in PharmAsia News
Executive Summary
India’s Glenmark has sped up its regulatory filings in a large set of countries, enthused by the prospects of filling unmet needs for HIV treatment regimens.